Other Clinical Trial - Evaluation of the Sensitivity of Merz Lips Fullness

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

Primary objective:

- To evaluate the sensitivity of the Merz Lip Fullness Assessment Scale (MLFAS).

Secondary objectives:

- To evaluate the clinical aesthetic improvement outcome in lips appearance four weeks after Etermis 4® injection.

- To evaluate safety/tolerability of Etermis 4® treatment in lips.

NCT number	NCT03256942
Study type	Interventional
Source	Merz Pharmaceuticals GmbH
Contact
Status	Completed
Phase	N/A
Start date	August 16, 2017
Completion date	November 17, 2017

Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation — ELISE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms